Carisma Therapeutics (NASDAQ:CARM) Insider Michael Klichinsky Sells 119,347 Shares

Carisma Therapeutics Inc. (NASDAQ:CARM) insider Michael Klichinsky sold 119,347 shares of Carisma Therapeutics stock in a transaction that occurred on Friday, October 3rd. The stock was sold at an average price of $0.26, for a total value of $31,030.22. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Michael Klichinsky also recently made the following trade(s):

• On Thursday, October 2nd, Michael Klichinsky sold 200,000 shares of Carisma Therapeutics stock. The stock was sold at an average price of $0.25, for a total value of $50,000.00.
• On Wednesday, October 1st, Michael Klichinsky sold 165,000 shares of Carisma Therapeutics stock. The stock was sold at an average price of $0.26, for a total value of $42,900.00.

Carisma Therapeutics Price Performance

Shares of NASDAQ:CARM opened at $0.26 on Friday. The business’s 50 day moving average price is $0.30 and its 200-day moving average price is $0.30. The firm has a market capitalization of $10.90 million, a PE ratio of -0.17 and a beta of 2.06. Carisma Therapeutics Inc. has a 1 year low of $0.14 and a 1 year high of $1.27.

Institutional Investors Weigh In On Carisma Therapeutics

A hedge fund recently bought a new stake in Carisma Therapeutics stock. Jane Street Group LLC bought a new stake in Carisma Therapeutics Inc. (NASDAQ:CARM) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 150,810 shares of the company’s stock, valued at approximately $59,000. Jane Street Group LLC owned 0.36% of Carisma Therapeutics as of its most recent SEC filing. 44.27% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

CARM has been the topic of a number of recent research reports. D. Boral Capital reissued a “buy” rating and set a $1.00 price objective on shares of Carisma Therapeutics in a research note on Friday, August 8th. Evercore ISI raised Carisma Therapeutics to a “strong-buy” rating in a research note on Tuesday, July 15th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Carisma Therapeutics in a research note on Saturday, September 27th. Two investment analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Carisma Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $1.93.

About Carisma Therapeutics

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.